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Abstract Evidence suggests an important role of elevated serum
lipoproteins in the progression of renal glomerulosclerosis. We
report here that lipoprotein (a) (Lp(a)) increased phosphorylation
and activity of mitogen activated protein kinase (MAPK) in
human mesangial cells. When protein kinase C (PKC) was
depleted by long-term incubation with the phorbol 12-O-
myristate 13-acetate the effect of Lp(a) on MAPK activation
was completely inhibited. Forskolin, a stimulator of the adenylyl
cyclase, and dibutyryl-cAMP reduced the effect of Lp(a) on
MAPK phosphorylation and activation. We conclude that Lp(a)
stimulates the MAPK cascade via activation of PKC and that
activation of protein kinase A counteracts Lp(a) induced MAPK
activation in human mesangial cells.
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1. Introduction
Lipoprotein abnormalities are a characteristic feature of
chronic renal insu⁄ciency [1]. It has been suggested that alter-
ations of the lipoprotein metabolism contribute to the pro-
gression of glomerulosclerosis [2,3]. Biochemical and histolog-
ical similarities between atherosclerosis and glomerulosclerosis
have been proposed [4], and in animal studies lipid lowering
treatment was shown to be bene¢cial in slowing the progres-
sion of renal disease [5,6]. Lipoprotein (a) (Lp(a)) is recog-
nized as an independent risk factor of atherosclerosis and
Lp(a) serum concentrations were found to be elevated in pa-
tients with nephrotic syndrome. In£ammation or damage of
the glomerular barrier may facilitate access of macromolecules
to the mesangium. This in£ux may result in cytokine activa-
tion and secondary proliferative responses. In vitro experi-
ments showed that low density lipoprotein (LDL) and Lp(a)
bind to mesangial and epithelial cells [7,8]. LDL stimulates
proliferation of these cells [9], whereas Lp(a) stimulates pro-
liferation and increases mRNA levels for c-myc and c-fos in
rat mesangial cells [10]. LDL increases cytosolic calcium
([Ca2]i) in vascular smooth muscle cells and rat mesangial
cells [11^13]. Furthermore, LDL is growth promoting in hu-
man skin ¢broblasts of patients with familial hypercholester-
olemia lacking the LDL receptor, suggesting an independent
e¡ect of the classic LDL receptor [14]. LDL activates the
p42ERK2/p44ERK1 kDa mitogen activated protein kinase
(MAPK) in vascular smooth muscle cells, ¢broblasts, and
rat mesangial cells [15,16]. We have recently shown that
Lp(a) increases [Ca2]i and inositol 1,4,5-trisphosphate (IP3)
levels by a pertussis toxin (PTX) sensitive Gi coupled receptor
and stimulates proliferation of human mesangial cells (in
press). The growth stimulatory e¡ect of Lp(a) suggests that
signal transduction through the MAPK is one of the down-
stream events of Lp(a). In the present study we investigated
the e¡ect of Lp(a) on MAPK activity. In addition, we exam-
ined the e¡ect of adenylyl cyclase activation on Lp(a) induced
MAPK activation, since substances which increase cAMP are
known to counteract proliferative and vasoconstrictive e¡ects
in mesangial cells [17].
2. Materials and methods
2.1. Materials
Enhanced chemiluminescence (ECL) reagents, cAMP assay,
[Q-32P]ATP, secondary horseradish peroxidase (HRP) labeled antibod-
ies and X-ray ¢lms were obtained from Amersham Inc. (Little Chal-
font, UK). MAPK assay was from Stratagene (La Jolla, CA, USA),
RPMI 1640 medium and fetal calf serum (FCS) were from Gibco
(Gaithersburg, MD, USA). Nitrocellulose membrane (pore size 0.2
Wm) was from Schleicher and Schuell (Dassel, Germany), anti-phos-
photyrosine antibody was purchased from ICN (Costa Mesa, CA,
USA). Anti-p42ERK antibody and forskolin were from Calbiochem
(La Jolla, CA, USA), HRP labeled protein markers and the antibody
raised against dually phosphorylated MAPK (p42ERK2/p44ERK1) were
from New England Biolabs (Beverly, MA, USA). Phorbol 12-O-myr-
istate 13-acetate (PMA) and dibutyryl cAMP (db-cAMP) were from
Sigma (St. Louis, MO, USA).
2.2. Isolation of Lp(a)
Lp(a) was puri¢ed from the regenerate £uid of a dextran sulfate
column based LDL-apheresis system (Kanekafuchi MA 01 ^ Lipo-
sorber LA 15) as described [18]. Apo(a) phenotypes were determined
as an S2/S4 phenotype with the nomenclature of Utermann [19] with a
number of 22/31 kringle 4 repeats. For all experiments Lp(a) was
isolated from a single donor. Prior to use Lp(a) was extensively dia-
lyzed against phosphate bu¡ered saline (PBS).
2.3. Cell culture
Human mesangial cells were isolated by the sequential sieving tech-
nique from patients undergoing tumor nephrectomy. All experiments
were performed at passages 3^6. Mesangial cell cultures were identi-
¢ed by morphological and immunological characteristics such as pos-
itive staining for actin and negative staining for factor VIII and cy-
tokeratin. To exclude ¢broblast contamination cells were grown for
2 weeks in L-valine de¢cient RPMI 1640 supplemented with 10% FCS,
10 mM HEPES, pH 7.4, 1 mM sodium pyruvate, 100 U/ml penicillin/
streptomycin. Culture media were replaced three times per week.
2.4. Cell stimulation and preparation of cell extract
Cells were grown until subcon£uence in media supplemented with
10% FCS. Cells were washed once and made quiescent by a 48 h
incubation in serum-free medium. Lp(a) was added at di¡erent time
FEBS 21303 21-12-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 1 5 5 4 - 3
*Corresponding author. Fax: (49) (69) 6301-7810.
E-mail: mondorf@em.uni-frankfurt.de
FEBS 21303 FEBS Letters 441 (1998) 205^208
points. The incubations was terminated by washing cells twice with
ice-cold PBS. After scraping the cells were pelleted by centrifugation
and lysed in a bu¡er containing 1% Triton X-100, 0.32 M sucrose,
5 mM EDTA, 10 mM Tris-HCl (pH 8.0), 1 mM PMSF, 2 mM DTT,
10 mM sodium pyrophosphate, 200 mM sodium orthovanadate.
2.5. Measurement of MAPK activity
MAPK activity was measured by a commercially available in vitro
kinase assay using Phas I protein as a substrate. Cell lysates contain-
ing 20 Wg protein were incubated at 30‡C for 10 min in 4 Wl of
10Ukinase bu¡er (250 mM HEPES, 100 mM magnesium acetate,
500 WM ATP), 2 WCi [Q-32P]ATP and 10 Wg Phas I protein and
H2O to a ¢nal volume of 40 Wl. The reaction was stopped by adding
5 Wl of 0.25 M H3PO4. 20 Wl samples were spotted onto phosphocel-
lulose sheets and washed four times with 75 mM H3PO4. Thereafter,
the sheets were rinsed brie£y in 95% (v/v) ethanol and dried on a
paper towel. Radioactivity of the sheets was measured by determina-
tion of Cerenkov radiation. Controls lacking the cell lysates, Phas I or
both were run in parallel. Activities are expressed as phosphotransfer
per minute per mg protein.
2.6. Immunoblotting of MAPK
Cell lysates were protein matched (150 Wg/lane) and separated by
SDS-PAGE and electrotransferred to nitrocellulose sheets. Western
blotting was carried out as described recently [20]. Antigen-antibody
complexes were visualized using secondary HRP conjugated antibod-
ies and the ECL system.
2.7. Measurement of cAMP
30 000 cells were plated on 36 mm culture dishes and allowed to
reach subcon£uence over 7 days. For measurement of intracellular
cAMP, the medium was replaced by serum-free medium containing
the indicated concentration of forskolin or Lp(a) for 1 h. The stim-
ulation was terminated by aspiration of the medium and the addition
of ice-cold 65% ethanol. The cAMP content of the samples was de-
termined using a radioimmunoassay and was performed according to
the protocol provided by the manufacturer.
2.8. Miscellaneous
Protein was measured according to the method of Bradford [21]
using bovine serum albumin as a standard. The data presented are
means þ S.D. Statistical signi¢cance was calculated using Student’s
t-test for paired values.
3. Results
3.1. E¡ects of Lp(a) on MAPK phosphorylation and activation
To demonstrate activation of MAPK we performed immu-
noblots with a speci¢c anti-phospho-MAPK antibody, which
detects the dually phosphorylated form of p44ERK1 and
p42ERK2. Lp(a) (10 Wg/ml) caused an increase in p42ERK2/
p44ERK1 phosphorylation between 5 and 10 min incubation.
After 30 min and 60 min incubation phosphorylation of
p42ERK2/p44ERK1 declined to basal levels (Fig. 1A). Reprobing
of the immunoblots with the p42ERK2 speci¢c antibody re-
vealed equal loading of the lanes.
To measure MAPK activity cells were incubated with Lp(a)
(10 Wg/ml) for 5, 10, 30 and 60 min. MAPK was measured in
homogenates using Phas I protein as substrate. Lp(a) induced
MAPK activity increased signi¢cantly (P6 0.001) from a
basal level of 5.35 þ 0.36 pmol/min/mg protein to 9.13 þ 0.67
(5 min) and 7.51 þ 0.53 (10 min). MAPK activities were not
di¡erent from the basal level at 30 min (5.08 þ 1.34 pmol/min/
mg protein) and 60 min (4.10 þ 0.61 pmol/min/mg protein).
The e¡ect of epidermal growth factor (EGF) (Fig. 2) was
considerably higher compared to Lp(a) (EGF 22.72 þ 1.81
pmol/min/mg protein, Lp(a) 18.84 þ 0.8 pmol/min/mg protein;
P6 0.001 vs. control).
3.2. Role of protein kinase C (PKC) in Lp(a) induced MAPK
phosphorylation
When PKC was depleted by overnight treatment of the cells
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Fig. 1. A: E¡ect of Lp(a) on phosphorylation of MAPK in human
mesangial cells. Cells were incubated with Lp(a) (10 Wg/ml) for the
indicated time periods. After lysis of the cells equal amounts of pro-
tein (150 Wg) were immunoblotted with an anti-phospho-MAPK
antibody. After stripping the same blot was reprobed with an anti-
p42ERK2 antibody. Lane 1: basal; lane 2: Lp(a) 5 min; lane 3:
Lp(a) 10 min; lane 4: Lp(a) 30 min; lane 5: Lp(a) 60 min; lane 6:
blank; lane 7: positive control consisting of phosphorylated
p44ERK1 ; lane 8: molecular weight marker. B: E¡ect of Lp(a) on
activation of MAPK in cultured human mesangial cells. The activity
of MAPK was measured by in vitro kinase assay. Cells were incu-
bated with Lp(a) (10 Wg/ml) for 5, 10, 30 and 60 min. Values are
mean þ S.D. (n = 4). Asterisks indicate signi¢cant di¡erences
(**P6 0.001).
Fig. 2. E¡ect of forskolin and db-cAMP on Lp(a) induced activa-
tion of MAPK in human cultured mesangial cells. The activity of
MAPK was measured by in vitro kinase assay. Cells were incubated
with Lp(a) (10 Wg/ml) or EGF (10 ng/ml) for 10 min or were prein-
cubated with forskolin (100 WM) or db-cAMP (1 mM) for 30 min
prior to the addition of Lp(a). Values are mean þ S.D. (n = 4). Aster-
isks indicate signi¢cant di¡erences (*P6 0.05; **P6 0.01).
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with PMA (100 nM), neither Lp(a) (10 Wg/ml) nor PMA (500
nM) caused a signi¢cant increase in phosphorylation of
MAPK (Fig. 3), whereas the e¡ect of EGF remained un-
changed (data not shown). Thus, activation of MAPK by
Lp(a) appears to depend on activation of PKC.
3.3. E¡ects of cAMP on Lp(a) induced phosphorylation of
MAPK
Substances known to increase the cAMP level are known to
inhibit proliferation of mesangial cells and phosphorylation of
mesangial MAPK [22]. As illustrated in Fig. 4, Lp(a) (10 Wg/
ml) had no signi¢cant e¡ect on cAMP concentration, whereas
forskolin (50 WM), a direct stimulator of adenylyl cyclase,
increased the cellular cAMP level.
Preincubation of cells with forskolin (100 WM) or db-cAMP
(1 mM) inhibited Lp(a) (10 Wg/ml) induced MAPK phospho-
rylation (Fig. 5). As shown in Fig. 2 forskolin (100 WM) and
db-cAMP (1 mM) reduced MAPK activity only partially from
18.84 þ 0.79 pmol/min/mg protein to 14.39 þ 1.42 pmol/min/
mg protein and 13.93 þ 1.04 pmol/min/mg protein respectively
(P6 0.01 vs. Lp(a)).
4. Discussion
The interaction of Lp(a) with glomerular mesangial cells
has been investigated. It was shown that Lp(a) is taken up
by rat and human mesangial cells through a typical feature of
a receptor mediated process, i.e. Michaelis-Menten kinetics
and saturability, suggesting distinct receptor sites for Lp(a).
Furthermore, glomerular deposition of apolipoprotein (a) and
functional properties of Lp(a) have been shown such as stim-
ulation of cell proliferation and expression of c-myc and c-fos
in rat mesangial cells [10,23,24]. The growth stimulatory e¡ect
of Lp(a) in human mesangial cells suggests that the activation
of MAPK by Lp(a) might be an important mechanism in
Lp(a) signaling. Therefore, in the present study, we assessed
the e¡ect of Lp(a) on MAPK activity in human mesangial
cells and the in£uence of PKC and protein kinase A (PKA)
activation in this process.
MAPKs play a key role in cellular proliferation and di¡er-
entiation [25]. Incubation of mesangial cells with Lp(a) phos-
phorylated mainly p42ERK2 and p44ERK1 and rapidly stimu-
lated phosphorylation of exogenous Phas I protein. The time
course of MAPK phosphorylation was similar to those re-
ported for endothelin I and angiotensin II in mesangial cells
[26,27]. We have thus concluded that Lp(a) stimulation of
human mesangial cells can increase p42ERK2/p44ERK1 phos-
phorylation. Other lipoproteins such as LDL, mildly oxida-
tively modi¢ed and oxidatively modi¢ed LDL and high den-
sity lipoprotein (HDL) also activated p42ERK2 [15]. These
e¡ects were mediated by elevation of [Ca2]i and activation
of PKC.
Our ¢nding that Lp(a) did not activate MAPK in PKC
depleted cells suggests that PKC is involved in Lp(a) induced
MAPK activation. Other experiments with human skin ¢bro-
blasts have shown that lipoproteins such as LDL and HDL3
stimulated PKC by a phosphoinositide speci¢c pathway [28].
It is known that agents which increase the cAMP concen-
tration counteract the e¡ects of vasoconstrictive and prolifer-
ative agents in mesangial cells [29], whereas in PC12 and COS-
7 cells cAMP stimulated MAPK [30,31]. We hypothesized
that the e¡ects of Lp(a) might also be inhibited by an increase
in cAMP. Preincubation with forskolin or db-cAMP inhibited
the Lp(a) induced stimulation of MAPK. However, the inhib-
itory e¡ect was incomplete. MAPK activity measured by in
vitro kinase assay did not return to control level. Thus, for-
skolin and db-cAMP only partially inhibited Lp(a) signaling.
Other investigators have shown that cyclic nucleotides such as
cAMP and cGMP inhibited endothelin I induced activation of
MAPK at di¡erent steps [17], the former downstream of PKC
and the latter prior to PKC activation. Growth factor induced
stimulation MAPK is also inhibited by cAMP by interfering
with Raf-1 activation [22]. Since PKC can directly phospho-
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Fig. 5. E¡ect of forskolin and db-cAMP on Lp(a) induced MAPK
phosphorylation. Cell lysates were matched for protein and immu-
noblotted with an anti-phospho-MAPK antibody. Lanes 1 and 5:
control; lane 2: Lp(a) (10 Wg/ml) for 30 min; lane 3: preincubation
of the cells for 30 min with forskolin (100 WM) followed by incuba-
tion with Lp(a) (10 Wg/ml) for 30 min; lane 4: preincubation for 30
min with db-cAMP (1 mM) followed by incubation with Lp(a) (10
Wg/ml) for 30 min; lane 6: incubation for 30 min with forskolin;
lane 7: incubation for 30 min with db-cAMP; lane 8: blank; lane
9: positive control of phosphorylated p44ERK1 ; lane 10: molecular
weight markers.
Fig. 4. E¡ect of Lp(a) and forskolin on the cellular cAMP concen-
tration. Cells were treated with 10 Wg/ml Lp(a) and 50 WM forskolin
for 1 h and cAMP accumulation was measured as described in Sec-
tion 2. Values are mean þ S.D. (n = 4). Asterisks indicate a signi¢-
cant di¡erence (**P6 0.01).
Fig. 3. In£uence of PKC on Lp(a) induced MAPK phosphorylation.
After lysis of the cells equal amounts of protein (150 Wg) were im-
munoblotted with an anti-phospho-MAPK antibody. Cells were
stimulated with Lp(a) (10 Wg/ml) (lane 3) or PMA (0.5 WM) (lane 4)
for 30 min. To deplete cells from PKC, cells were preincubated for
12 h with PMA (0.5 WM). Then, the cells were incubated with Lp(a)
(lane 1) or PMA (lane 2). Lane 5: blank; lane 6: positive control
consisting of phosphorylated p44ERK1 ; lane 7: molecular weight
marker.
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rylate Raf-1 [32], we speculate that cAMP also inhibits acti-
vation of Raf-1 by Ras in our experiments.
Taken together, we have shown for the ¢rst time that Lp(a)
stimulates MAPK in a human primary cell. Whether these
e¡ects contribute to the pathophysiology of glomerulosclero-
sis requires further investigation.
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